| Inhibition of Neuroblastoma Tumor Growth by Targeted Delivery of MicroRNA-34a Using Anti-Disialoganglioside GD2 Coated Nanoparticles A Tivnan, WS Orr, V Gubala, R Nooney, DE Williams, C McDonagh, ... PloS one 7 (5), e38129, 2012 | 272 | 2012 |
| Sexual dimorphism in colon cancer M Abancens, V Bustos, H Harvey, J McBryan, BJ Harvey Frontiers in Oncology 10, 607909, 2020 | 172 | 2020 |
| Estrogen reduces lipid content in the liver exclusively from membrane receptor signaling A Pedram, M Razandi, F O’Mahony, H Harvey, BJ Harvey, ER Levin Science signaling 6 (276), ra36-ra36, 2013 | 126 | 2013 |
| The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro O Piskareva, H Harvey, J Nolan, R Conlon, L Alcock, P Buckley, ... Cancer letters 364 (2), 142-155, 2015 | 98 | 2015 |
| MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1 L Creevey, J Ryan, H Harvey, IM Bray, M Meehan, AR Khan, RL Stallings Molecular cancer 12, 1-12, 2013 | 89 | 2013 |
| Bidirectional KCNQ1: β-catenin interaction drives colorectal cancer cell differentiation R Rapetti-Mauss, V Bustos, W Thomas, J McBryan, H Harvey, N Lajczak, ... Proceedings of the National Academy of Sciences 114 (16), 4159-4164, 2017 | 80 | 2017 |
| A physiologically relevant 3D collagen-based scaffold–neuroblastoma cell system exhibits chemosensitivity similar to orthotopic xenograft models C Curtin, JC Nolan, R Conlon, L Deneweth, C Gallagher, YJ Tan, ... Acta biomaterialia 70, 84-97, 2018 | 68 | 2018 |
| Modulation of chemotherapeutic drug resistance in neuroblastoma SK‐N‐AS cells by the neural apoptosis inhibitory protein and mi R‐520f H Harvey, O Piskareva, L Creevey, LC Alcock, PG Buckley, MJ O'Sullivan, ... International journal of cancer 136 (7), 1579-1588, 2015 | 59 | 2015 |
| GPER mediates differential effects of estrogen on colon cancer cell proliferation and migration under normoxic and hypoxic conditions V Bustos, ÁM Nolan, A Nijhuis, H Harvey, A Parker, R Poulsom, ... Oncotarget 8 (48), 84258, 2017 | 58 | 2017 |
| Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase deficiency in patients with colorectal cancer: a single-institution experience C Murphy, S Byrne, G Ahmed, A Kenny, J Gallagher, H Harvey, ... Dose-Response 16 (4), 1559325818803042, 2018 | 54 | 2018 |
| Sex Differences in Colon Cancer: Genomic and Nongenomic Signalling of Oestrogen BJ Harvey, HM Harvey Genes 14 (12), 2225, 2023 | 7 | 2023 |
| The impact of a national cyberattack affecting clinical trials: the cancer trials Ireland experience H Harvey, H Carroll, V Murphy, J Ballot, M O'Grady, D O'Hare, G Lawler, ... JCO Clinical Cancer Informatics 7, e2200149, 2023 | 7 | 2023 |
| Dealing with digital paralysis: Surviving a cyberattack in a National Cancer center RJ Keogh, H Harvey, C Brady, E Hassett, SJ Costelloe, MJ O’Sullivan, ... Journal of Cancer Policy 39, 100466, 2024 | 5 | 2024 |
| The impact of a ransomware cyber attack on a breast cancer center. H Harvey, R Joyce, K Rock, TJ Browne, MW Bennett, F O'Connell, ... Journal of Clinical Oncology 40 (16_suppl), e13620-e13620, 2022 | 2 | 2022 |
| Impact of Conti ransomware attack on cancer trials Ireland sites. H Harvey, V Amberger-Murphy, J Ballot, M O'Grady, D O'Hare, G Lawler, ... Journal of Clinical Oncology 40 (16_suppl), e13614-e13614, 2022 | 2 | 2022 |
| Corrigendum to “The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro”[Cancer Lett 364 (2015) 142–155] O Piskareva, H Harvey, J Nolan, R Conlon, L Alcock, P Buckley, ... Cancer Letters 2 (369), 428, 2015 | 2 | 2015 |
| Functional analysis of miRNA in chemotherapy resistant neuroblastoma HM Harvey, IM Bray, RL Stallings Cancer Research 72 (8_Supplement), 816-816, 2012 | 1 | 2012 |
| Comparison of long-term outcomes for neoadjuvant chemoradiation (NA-CRT) followed by surgery versus (V) definitive chemoradiation (D-CRT) in localized gastroesophageal cancer … RA McLaughlin, D Sharma, Y Bach, AR Farooq, N Ghazali, H Harvey, ... Journal of Clinical Oncology 43 (4_suppl), 371-371, 2025 | | 2025 |
| Nanoparticle-based drug delivery in advanced pancreatic ductal adenocarcinoma: is it time to deliver yet? Z Coyne, RA McLaughlin, H Harvey, JJ Knox AME Clinical Trials Review 2, 2024 | | 2024 |
| PLK1 and its role in the evolving landscape of KRAS-mutated colorectal cancer H Harvey, EX Chen Journal of Gastrointestinal Oncology 15 (4), 1987, 2024 | | 2024 |